CPRX · As filed with the SEC

Catalyst Pharmaceuticals income statement, by fiscal year

The statement as Catalyst Pharmaceuticals presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME · USD

USDFY2025
Year ended Dec 31, 2025
FY2024
Year ended Dec 31, 2024
FY2023
Year ended Dec 31, 2023
FY2022
Year ended Dec 31, 2022
Revenues:
Total revenues588,989,000491,734,000398,204,000214,203,000
License and other revenue182,0002,407,0001,702,000265,000
Product revenue, net588,807,000489,327,000396,502,000213,938,000
Operating costs and expenses:
Cost of sales87,253,00068,845,00051,967,00034,393,000
Research and development12,709,00012,648,00093,150,00019,789,000
Selling, general and administrative193,751,000177,740,000133,710,00058,183,000
Amortization of intangible assets37,498,00037,377,00032,565,000—
Total operating costs and expenses331,211,000296,610,000311,392,000112,365,000
Operating income257,778,000195,124,00086,812,000101,838,000
Other income, net25,737,00021,139,0007,699,0002,881,000
Net income before income taxes283,515,000216,263,00094,511,000104,719,000
Income tax provision69,189,00052,374,00023,101,00021,640,000
Net income214,326,000163,889,00071,410,00083,079,000
Net income per share:
Basic1.751.380.670.8
Diluted1.681.310.630.75
Weighted average shares outstanding:
Basic122,290,866118,457,673106,279,736103,374,606
Diluted127,257,929124,943,603113,753,154111,375,631
Other comprehensive income (Note 4):
Unrealized gain (loss) on available-for-sale securities, net of tax of $0, ($20) and $4, respectively(64,000)50,000(10,000)172,000
Comprehensive income214,262,000163,939,00071,400,00083,251,000

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.